Clinical effects of antidiabetic drugs on psoriasis:The perspective of evidence-based medicine  

作　　者：Mei-Xian Zhang Bo-Yuan Zheng Hai-Xiao Chen Ching-Wen Chien 

机构地区：[1]Evidence-based Medicine Center,Taizhou Hospital of Zhejiang Province,Wenzhou Medical University,Linhai 317000,Zhejiang Province,China [2]Public Laboratory,Taizhou Hospital of Zhejiang Province,Wenzhou Medical University,Linhai 317000,Zhejiang Province,China [3]Institute for Hospital Management,Tsing Hua University,Shenzhen Campus,Shenzhen 518055,Guangdong Province,China [4]Department of Orthopedics,Taizhou Hospital of Zhejiang Province,Wenzhou Medical University,Linhai 317000,Zhejiang Province,China

出　　处：《World Journal of Diabetes》2021年第8期1141-1145,共5页世界糖尿病杂志（英文版）（电子版）

摘　　要：Psoriasis and diabetes shared common underlying pathophysiological mechanisms.Emerging data suggested that antidiabetic medications may improve the psoriasis severity in patients with diabetes mellitus.Several hypoglycemic agents including thiazolidinediones,glucagon-like peptide-1 receptor agonists,dipeptidyl peptidase-4 inhibitors,and biguanides have been reported to make a remarkable reduction in the Psoriasis Area and Severity Index score from baseline.This antipsoriatic effect could be mediated not only by the glucoselowering action of these agents but also via inhibition of keratinocyte over proliferation,increase expression of differentiation markers,suppression the immune inflammatory pathway,and blocking the calcium channels and mitogen-activated protein kinase signaling pathways.On the other hand,there was no significant increase in adverse reactions associated with the treatment of pioglitazone or metformin.However,previous studies often had the relatively short duration of the trials,and did not have enough power to assess recurrence of psoriasis.Potential bias in the study and missing data could undermine the reliability of the results.Therefore,the appropriately randomized controlled studies with large sample sizes and long-term durations in various psoriasis patients are warranted for further support.

关 键 词：PSORIASIS Hypoglycemic agents THIAZOLIDINEDIONES Glucagon-like peptide-1 receptor agonists Dipeptidyl peptidase-4 inhibitors BIGUANIDES Antipsoriatic effect Evidence-based medicine 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]